GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

Glax­o­SmithK­line CEO Em­ma Walm­s­ley is adding an­oth­er sci­en­tist to the com­pa­ny’s board. Ear­ly Wednes­day — along­side their Q3 up­date — Walm­s­ley put out word that Har­ry “Hal” Di­etz, a pro­fes­sor of ge­net­ics and med­i­cine at Johns Hop­kins, will be jump­ing on board as a non-ex­ec­u­tive di­rec­tor.

Di­etz’s ap­point­ment puts him on the same path tak­en by 2 oth­er sci­en­tists: Jesse Good­man, for­mer chief sci­en­tist at the FDA, and Lau­rie Glim­ch­er, CEO of the Dana-Far­ber Can­cer In­sti­tute.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER